The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 7 of the 85 sources its claims cite were checked for support.
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Open accessAbstract
Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis remains unfavourable because of the occurrence of either intrinsic or acquired resistance. We reviewed the published literature and abstracts of oral and poster presentations from international conferences addressing EGFR-TKIs resistance mechanisms discovered in preclinical models and in patients with NSCLC. The molecular heterogeneity of lung cancer has several implications in terms of possible mechanisms of either intrinsic or acquired resistance to EGFR-targeted inhibitors. Several mechanisms of resistance have been described to EGFR-TKIs, such as the occurrence of secondary mutation (T790M, C797S), the activation of alternative signalling (Met, HGF, AXL, Hh, IGF-1R), the aberrance of the downstream pathways (AKT mutations, loss of PTEN), the impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism) and histological transformation. Although some of the mechanisms of resistance have been identified, much additional information is needed to understand and overcome resistance to EGFR-TKI agents. The majority of resistance mechanisms described are the result of a selection of pre-existing clones; thus, studies on the mechanisms by which subclonal alterations have an impact on tumour biology and influence cancer progression are extremely important in order to define the best treatment strategy.
Overview
CoChat Summary
TL;DR
This review summarizes intrinsic and acquired mechanisms of resistance to EGFR-targeted drugs in non-small cell lung cancer (NSCLC), including secondary EGFR mutations, alternative pathway activation, downstream pathway alterations, apoptosis impairment, and histological transformation. It emphasizes that resistance often reflects selection of pre-existing subclones and that further work is needed to define optimal treatment after progression.
Key findings
- The major acquired resistance mechanism to first-generation EGFR-TKIs is the exon 20 T790M substitution, accounting for about half of cases; third-generation EGFR-TKIs such as AZD9291 can be followed by the tertiary C797S mutation, which confers cross-resistance to all third-generation inhibitors.
- In 15 patients with resistance to AZD9291 analysed by next-generation sequencing of cell-free DNA, distinct EGFR genotypes were acquired C797S together with T790M in 40%, T790M without C797S in 33%, and loss of T790M without C797S in 27%.
- Alternative pathway activation is the second most common resistance mechanism; MET amplification accounts for 5–20% of acquired resistance causes, while ErbB2 amplification was responsible for acquired resistance in 12% of cases.
- Exon 20 insertions occur in 1–10% of all EGFR mutations and are the most important frequent drug-resistant EGFR mutations; BIM deletion polymorphisms or low-to-intermediate BIM mRNA levels are associated with reduced clinical efficacy of EGFR-TKIs.
Methods
- Narrative review of peer-reviewed publications listed in PubMed since the discovery of EGFR-activating mutations in 2004, plus oral and poster abstracts from ASCO and ESMO from 2010 to 2015.
- Search strategy combined keywords for “NSCLC,” “EGFR mutations,” and “resistance”; articles or abstracts in languages other than English were excluded.
- The review synthesizes preclinical models and patient data, including phase III trial results, clinical definitions/subtyping of acquired resistance, and molecular mechanisms such as secondary mutations, phenotypic transformation, and alternative pathway activation.
Limitations
- The paper states that much additional information is needed to understand and overcome resistance to EGFR-TKI agents, that the optimum treatment after disease progression is not yet clear, and that the choice of best first-line EGFR-TKI remains debated.
- The paper notes that the Jackman clinical definition of acquired resistance needed further clinical validation, that the most informative method to define MET amplification is not established, and that serial tumour sampling to monitor clonal evolution poses practical challenges and is not standard practice.
- Evident from the text: this is a narrative review rather than a systematic review or meta-analysis, with selection limited to English-language PubMed publications and ASCO/ESMO abstracts from 2010–2015, so the synthesis may be subject to selection and publication biases.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
5 Valid · 0 Not valid · 52 Not checked · 10 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These agents are designed to specifically inhibit mutant EGFR (ie, 19del-EGFR, L858R-EGFR and/or T790M+EGFR), sparing the WT receptor.14–18”
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Introduction
What the sources say
- Supportedcites [14] Zhou W, Ercan D, Chen L Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462: 1070– 4. 10.1038/nature08622 20033049 PMC2879581 source
The Abstract and Discussion of Zhou et al. (2009) state that the pyrimidine agents (WZ3146, WZ4002, WZ8040) were screened specifically against EGFR T790M and 'are unique in that they inhibit both the drug sensitizing and resistance mutations but are selective against WT EGFR', covering delE746_A750 (PC9/PC9GR), L858R/T790M (H1975) and Ba/F3 T790M. The results section confirms WT sparing: 3-100-fold less potent in EGFR WT HN11 and EGFRvIII Ba/F3 cells, 100-fold less effective at inhibiting WT EGFR phosphorylation, and no inhibition of WT EGFR in mouse skin hair bulb in vivo. The only element not the paper's own wording is the class label 'third-generation', which is the citing authors' taxonomy; the attributed content (mutant-selective design sparing WT across 19del/L858R/T790M) is stated. (LLM, conf=0.88)
- Supportedcites [15] Cross DAE, Ashton SE, Ghiorghiu S AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 10.1158/2159-8290.CD-14-0337 24893891 PMC4315625 source
The Introduction (p. 1) states directly that "This has led to the development of 'third generation' EGFR TKIs that are designed to target T790M and EGFR TKI-sensitizing mutations more selectively than wild-type EGFR," addressing both the mutant-selective design and the sparing of WT receptor. The same Introduction defines the EGFR TKI-sensitizing mutations as exon 19 in-frame deletions (ex19del) and L858R, so the claim's enumeration (19del, L858R, T790M) matches the source's own definitions. The Results ("AZD9291 potently and selectively targets mutant EGFR cell lines in vitro") and Discussion reinforce this with the wide mutant-vs-wild-type selectivity margin (e.g., ~200-fold over wild-type for L858R/T790M), consistent with the design intent attributed. (LLM, conf=0.90)
- Not checked yetcites [16] Soria J, Sequist LV, Goldman JW Interim phase 2 results of study CO-1686-008: a phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer. Eur J Cancer 2014; 50: 199 10.1016/S0959-8049(14)70731-2 source
- Not checked yetcites [17] Tan CS, Cho BC, Soo RA Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. Lung Cancer 2016; 93: 59– 68. 26898616 source
- Not checked yetcites [18] Murakami H, Nokihara H, Shimizu T 9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation. Eur J Cancer 2014; 50: 198. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The presence of the T790M mutation was observed in approximately 50% of the cases in which biopsy was obtained at the time of relapse following gefitinib or erlotinib treatment in patients with the exon 19 deletion or the L858R EGFR mutation.”
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Mechanisms of acquired resistance to EGFR-TKIs in NSCLC > 1. Insurgence of secondary mutations in the EGFR gene
What the sources say
- Partly supportedcites [14] Zhou W, Ercan D, Chen L Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462: 1070– 4. 10.1038/nature08622 20033049 PMC2879581 sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) reports that T790M is detected in 50% of patients clinically resistant to gefitinib or erlotinib and identifies exon 19 deletion and L858R as common activating mutations. It does not specify that the 50% figure comes from biopsies obtained at relapse or give that figure specifically for patients with those two mutations. (LLM, conf=0.85)
- Supportedcites [15] Cross DAE, Ashton SE, Ghiorghiu S AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 10.1158/2159-8290.CD-14-0337 24893891 PMC4315625 source
The Introduction identifies exon 19 deletions and L858R as the activating mutations associated with response to gefitinib or erlotinib, then says T790M is detected in tumor cells from more than 50% of patients after disease progression. The Discussion likewise reports T790M in more than half of patients’ tumor cells at progression; this supports the claim’s approximate figure for tissue assessed at relapse. (LLM, conf=0.88)
- Not checked yetcites [16] Soria J, Sequist LV, Goldman JW Interim phase 2 results of study CO-1686-008: a phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer. Eur J Cancer 2014; 50: 199 10.1016/S0959-8049(14)70731-2 source
- Not checked yetcites [17] Tan CS, Cho BC, Soo RA Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. Lung Cancer 2016; 93: 59– 68. 26898616 source
- Not checked yetcites [18] Murakami H, Nokihara H, Shimizu T 9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation. Eur J Cancer 2014; 50: 198. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, treatment with navitoclax, an inhibitor of the antiapoptotic factors BCL-xL and BCL-2, restored sensitivity.31”
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Mechanisms of acquired resistance to EGFR-TKIs in NSCLC > 1. Insurgence of secondary mutations in the EGFR gene
What the sources say
- Supportedcites [31] Hata AN, Niederst MJ, Archibald HL Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 2016; 22: 262– 9. 10.1038/nm.4040 26828195 PMC4900892 source
The Results section identifies navitoclax as a dual BCL-XL and BCL-2 inhibitor and reports that combining it with the third-generation EGFR inhibitor WZ4002 increased apoptosis in resistant cell lines and induced regression of resistant xenograft tumors. This supports restored sensitivity in the studied resistance models. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recently, an integrated analysis in human EGFR-mutant NSCLC models and in a large clinical cohorts of paired NSCLC specimens from EGFR-TKI-treated patients demonstrated an upregulation of AXL tyrosine kinase receptor or of its ligand, GAS6, in resistant samples.”
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Mechanisms of acquired resistance to EGFR-TKIs in NSCLC > 2. Phenotypic transformation
What the sources say
- Supportedcites [40] Zhang Z, Lee JC, Lin L Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44: 852– 60. 10.1038/ng.2330 22751098 PMC3408577 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In particular, there is preclinical evidence that type II alveolar cells have the potential to differentiate into SCLC after the targeted disruption of Tp53 and Rb1.35”
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Mechanisms of acquired resistance to EGFR-TKIs in NSCLC > 2. Phenotypic transformation
What the sources say
- Supportedcites [35] Sutherland KD, Proost N, Brouns I Cell of origin of small lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011; 19: 754– 64. 10.1016/j.ccr.2011.04.019 21665149 source
The paper reports that targeted Trp53 and Rb1 loss in SPC-expressing cells led to SCLC in adult mice. The Discussion qualifies this as a capacity of a subset of SPC-positive, potentially progenitor-like cells, rather than all alveolar type II cells; the claim says only that they have the potential. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
20 more claims
Create a free account to see all 67 claims and to verify the 78 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 5
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Introduction
“resulting in higher response rates (RR) (up to 70%)”
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Introduction
“| OPTIMAL7 | Erlotinib | Gemcitabine–carboplatin | L858REx19D | 13.1 vs 4.6 | 83 vs 36 | 22.7 vs 28.9 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Introduction
“The two most common EGFR-activating mutations are small in-frame deletions in exon 19 (particularly E746-A750del) and amino acid substitution in exon 21 (leucine to arginine at codon 858 (L858R)), which collectively account for >90% of known activating EGFR mutations.”
§ Mechanisms of resistance to EGFR-targeted drugs: lung cancer > Mechanisms of primary resistance to EGFR-TKIs in NSCLC
“insertions or deletions (indels) in exon 19 (44% of all EGFR-activating mutations), insertions/duplications and point mutations in exon 20 and point mutations in exon 21 (41% of all EGFR-activating mutations).”
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Research works printed but not linked: 1
- Oxnard, 2015, Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer, J Thorac Oncol, 10, ORAL17.07
Cited by
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Yuan, M., Huang, L.-L., Chen, J.-H., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 679
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515
Hassell, B. A., Goyal, G., Lee, E., Sontheimer-Phelps, A., Levy, O., Chen, C. S., & Ingber, D. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.043 · Cited by 467
Oxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.013 · Cited by 438
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356
Metadata
- Authors
- Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Morgillo, Floriana
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2016
- Volume
- 1
- Issue
- 3
- Pages
- e000060
- ISSN
- 2059-7029 (ISSN-L)
- PMC
- PMC5070275
- OpenAlex
- W2352491315
- Cited by
- 476
- References
- 58
- Citations by year
- 2026: 32 · 2025: 52 · 2024: 49 · 2023: 45 · 2022: 46 · 2021: 49 · 2020: 69 · 2019: 53 · 2018: 47 · 2017: 33
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 1788 d)
- Locations
- ESMO Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion, public-domain)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (MFAG 2013-N.14392)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR tyrosine kinase inhibitors, drug resistance, non-small cell lung cancer, EGFR mutation, T790M mutation, C797S mutation, MET, hepatocyte growth factor, AXL, Hedgehog signaling, IGF-1 receptor, AKT mutations, PTEN loss, apoptosis, histologic transformation, clonal selection, subclonal heterogeneity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of resistance to EGFR-targeted drugs: lung cancer. https://app.cochat.ai/papers/10.1136/esmoopen-2016-000060
- The paper
- Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016). Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. https://doi.org/10.1136/esmoopen-2016-000060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.